4880 — CellSource Co Share Price
- ¥17bn
- ¥13bn
- ¥4bn
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | 0.53% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.8 | ||
Price to Tang. Book | 2.82 | ||
Price to Free Cashflow | 324.39 | ||
Price to Sales | 3.88 | ||
EV to EBITDA | 44.67 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 2.12% | ||
Return on Equity | 3.89% | ||
Operating Margin | 3.24% |
Financial Summary
Year End 31st Oct | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | ¥m | 1,855.47 | 2,922.23 | 4,273.83 | 4,510.54 | 4,355.06 | n/a | n/a | 22% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | -6.29 | +136.72 | +57.16 | -10.71 | -76.33 | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
CellSource Co., Ltd. is a Japan-based company engaged in regenerative medicine related business and consumer business. The Company operates in two business segments. The Regenerative Medicine Related business segment is engaged in the provision of contracted services for processing tissues and cells derived from fat and blood to medical institutions, and support services for regenerative medicine laws and regulations related to safety assurance such as regenerative medicine, as well as sales of medical equipment. The Consumer business segment is engaged in the sales of cosmetics and facial products to general consumers.
Directors
- Masato Tsumamoto PRE (39)
- Yujiro Sugi CFO (37)
- Hirohiko Hanaki EXO (52)
- Makoto Kagayama EXO (38)
- Katsuji Onishi EXO (48)
- Shinichi Sakurada EXO (40)
- Hajime Wakatsuki EXO (48)
- Takeshi Amemiya DRC (59)
- Masayuki Yamakawa DRC (57)
- Kumi Fujisawa IND (54)
- Norio Murakami IND (74)
- Takashi Sawada IND (64)
- Last Annual
- October 31st, 2024
- Last Interim
- October 31st, 2024
- Incorporated
- November 30th, 2015
- Public Since
- October 28th, 2019
- No. of Shareholders
- 11,312
- No. of Employees
- 157
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Tokyo Stock Exchange
- Shares in Issue
- 19,812,182

- Address
- 11F, Shibuya Cast, 1-23-21, Shibuya, SHIBUYA-KU, 150-0002
- Web
- https://www.cellsource.co.jp/
- Phone
- +81 364555308
- Auditors
- Ernst & Young ShinNihon LLC
Upcoming Events for 4880
Similar to 4880
Advantage Risk Management Co
Tokyo Stock Exchange
AHC
Tokyo Stock Exchange
Amvis Holdings
Tokyo Stock Exchange
Artra
Tokyo Stock Exchange
As Partners Co
Tokyo Stock Exchange
FAQ
As of Today at 03:59 UTC, shares in CellSource Co are trading at ¥852. This share price information is delayed by 15 minutes.
Shares in CellSource Co last closed at ¥852 and the price had moved by -36.56% over the past 365 days. In terms of relative price strength the CellSource Co share price has underperformed the Nikkei 225 Index by -40.92% over the past year.
The overall consensus recommendation for CellSource Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe CellSource Co dividend yield is 0.59% based on the trailing twelve month period.
Last year, CellSource Co paid a total dividend of ¥5, and it currently has a trailing dividend yield of 0.59%. We do not have any data on when CellSource Co is to next pay dividends.
We do not have data on when CellSource Co is to next pay dividends. The historic dividend yield on CellSource Co shares is currently 0.59%.
To buy shares in CellSource Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of ¥852, shares in CellSource Co had a market capitalisation of ¥17bn.
Here are the trading details for CellSource Co:
- Country of listing: Japan
- Exchange: TYO
- Ticker Symbol: 4880
Based on an overall assessment of its quality, value and momentum CellSource Co is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CellSource Co is ¥910. That is 6.81% above the last closing price of ¥852.
Analysts covering CellSource Co currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CellSource Co. Over the past six months, its share price has underperformed the Nikkei 225 Index by -43.99%.
As of the last closing price of ¥852, shares in CellSource Co were trading -31.39% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CellSource Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at ¥852.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
CellSource Co's management team is headed by:
- Masato Tsumamoto - PRE
- Yujiro Sugi - CFO
- Hirohiko Hanaki - EXO
- Makoto Kagayama - EXO
- Katsuji Onishi - EXO
- Shinichi Sakurada - EXO
- Hajime Wakatsuki - EXO
- Takeshi Amemiya - DRC
- Masayuki Yamakawa - DRC
- Kumi Fujisawa - IND
- Norio Murakami - IND
- Takashi Sawada - IND